Clinical Characteristics, Diagnosis, and Outcomes of Moxifloxacin-Associated Bilateral Acute Iris Transillumination.

PURPOSE: To explore the clinical characteristics of moxifloxacin-associated bilateral acute iris transillumination (BAIT) and provide references for diagnosis and treatment.

METHODS

The clinical reports of moxifloxacin-associated BAIT were collected before August 31, 2025, and the clinical data were extracted for retrospective analysis.

RESULTS

A total of 40 patients were included, with a median age of 53 (range 26, 77), including 28 (70.0%) women. The median occurrence time of BAIT was 14 days (rang 0.2, 60). Patients may present with photophobia (75.0%), decreased vision (67.5%), ocular pain (50.0%), and high intraocular pressure (32.5%). Ophthalmic examination shows iris transillumination. After the patients discontinued moxifloxacin and received topical steroids and anti-glaucoma treatment, the symptoms of most patients improved, while transillumination remained.

CONCLUSIONS

The patient developed ocular symptoms such as photophobia, ocular pain and decreased vision during the use of moxifloxacin, which requires further examination. If iris transillumination, ocular hypertension and acute pigment dispersion of the iris pigment epithelium are found during ophthalmic examination, the possibility of BAIT should be considered.